Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population

被引:22
作者
Lee, EJD
Zhao, B
Seow-Choen, F
机构
[1] Natl Univ Singapore, Dept Pharmacol, Singapore 119260, Singapore
[2] Singapore Gen Hosp, Dept Colorectal Surg, Singapore 0316, Singapore
来源
PHARMACOGENETICS | 1998年 / 8卷 / 06期
关键词
N-acetyltransferase-2; polymorphism; colorectal carcinoma;
D O I
10.1097/00008571-199812000-00008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human hepatic N-acetyltransferase (NAT2) is subject to a genetic polymorphism. Because NAT2 is an important enzyme for the detoxification and/or bioactivation of several carcinogenic arylamines, it has been postulated that the polymorphism of NAT2 gene is associated with the occurrence of colorectal and bladder carcinomas. Several mutations have been described in the human NAT2 gene that have been associated with reduced NAT2 activity. However, the majority are single base substitutions at positions 481 (NAT2*5A), 590 (NAT2*6A) and 857 (NAT2*7A) of the NAT2 gene. This study was performed to evaluate the relative distribution of NAT2 alleles and genotypes in 216 colorectal carcinoma patients and 187 normal individuals, The frequencies of NAT2 alleles and genotypes in the sampled Chinese population were characterized by allele-specific polymerase chain reaction. No differences were observed in the distribution of the genotypes coding rapid acetylation (homozygous wild-type and heterozygous wild-type with any of the mutations) when comparing colorectal carcinoma patients with control individuals (P > 0.05), However, the rapid acetylation genotype was associated with cancer occurring. on the right site of the colon, The frequencies of the NAT2*4, NAT2*5A, NAT2*6A and NAT2*7A alleles of the NAT2 gene (0.51, 0.07, 0.32 and 0.10, respectively) in control individuals were significantly different from those in patients (0.49, 0.06, 0.26 and 0.19, respectively, P < 0.01). There was a significant increase in the frequency of patients who were compound heterozygotes of NAT2*7A and a variant non-NAT2*7A allele, The NAT2*7A allele was also seen more frequently in distal cancer. Pharmacogenetics 8:513-517. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 25 条
[1]   MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS [J].
BLUM, M ;
DEMIERRE, A ;
GRANT, DM ;
HEIM, M ;
MEYER, UA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5237-5241
[2]   HUMAN ARYLAMINE N-ACETYLTRANSFERASE GENES - ISOLATION, CHROMOSOMAL LOCALIZATION, AND FUNCTIONAL EXPRESSION [J].
BLUM, M ;
GRANT, DM ;
MCBRIDE, W ;
HEIM, M ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1990, 9 (03) :193-203
[3]  
CARTWRIGHT RA, 1982, LANCET, V2, P842
[4]  
DEGUCHI T, 1990, J BIOL CHEM, V265, P12757
[5]   STRUCTURE AND RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM OF GENES FOR HUMAN LIVER ARYLAMINE N-ACETYLTRANSFERASES [J].
EBISAWA, T ;
DEGUCHI, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 177 (03) :1252-1257
[6]  
Evans D., 1992, Protein engineering: Proceedings of an AFRC conference on protein engineering in the agricultural and food industry, Selwyn College, Cambridge, 16-17 September 1991., P95
[7]   GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491
[8]   ACETYL COENZYME A-DEPENDENT METABOLIC-ACTIVATION OF N-HYDROXY-3,2'-DIMETHYL-4-AMINOBIPHENYL AND SEVERAL CARCINOGENIC N-HYDROXY ARYLAMINES IN RELATION TO TISSUE AND SPECIES-DIFFERENCES, OTHER ACYL DONORS, AND ARYLHYDROXAMIC ACID-DEPENDENT ACYLTRANSFERASES [J].
FLAMMANG, TJ ;
KADLUBAR, FF .
CARCINOGENESIS, 1986, 7 (06) :919-926
[9]   PREDICTION OF PHENOTYPE FOR ACETYLATION AND FOR DEBRISOQUINE HYDROXYLATION BY DNA-TESTS IN HEALTHY-HUMAN VOLUNTEERS [J].
GRAF, T ;
BROLY, F ;
HOFFMANN, F ;
PROBST, M ;
MEYER, UA ;
HOWALD, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :399-403
[10]  
GRANT DM, 1994, P 10 INT S MICR DRUG, P12